Latest Breaking News On - Announces highly favorable results - Page 1 : comparemela.com

The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.

Brownp tapinarofTodd zavodnickNew drug applicationPrescription drug user fee actPek pruritus numerical rating scaleSupplemental new drug applicationAtopic dermatitisAll asthAnnounces highly favorable resultsPediatric maximal usage study